Bio-Rad Laboratories

Norman Schwartz serves as Chairman, President, and CEO. He is the son of founders David and Alice Schwartz and has held the top executive role since 2003. The Schwartz family maintains a controlling equity interest through a dual-class stock structure.

Bio-Rad primarily operates a razor-and-blade model. Instruments like PCR thermal cyclers and gel electrophoresis systems generate upfront hardware revenue, but the recurring consumables — reagents, assay kits, and quality controls — drive the majority of the top line. Consumables represent roughly 75% of product revenue, providing a recurring base that funds R&D investment.

Bio-Rad held a significant equity stake in Sartorius AG, a German bioprocessing and lab equipment company, for decades. In 2021, Bio-Rad sold approximately $1.2 billion of Sartorius preferred shares, substantially monetizing the position. The remaining holding consists of ordinary Sartorius shares that carry voting rights, reflecting a long-standing, non-operating financial relationship rather than a strategic partnership.

Yes, in specific product categories. In qPCR instruments, droplet digital PCR, and protein electrophoresis, Bio-Rad competes directly with Thermo Fisher and Danaher's SCIEX and Beckman Coulter subsidiaries. In clinical diagnostics, competition comes from Abbott and Siemens Healthineers. Bio-Rad's narrower focus — it does not sell mass spectrometers or electron microscopes — differentiates it from the fully diversified conglomerates.

The Schwartz family controls a majority of voting power through Class B shares, which carry 10 votes per share compared to one vote for Class A. This structure allows management to prioritize internal R&D programs and acquisitions over short-term earnings targets. Consequently, Bio-Rad runs an R&D budget exceeding 8% of revenue, well above the public life sciences peer median.